Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
GAITHERSBURG, Md., Oct. 13, 2017 -- Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr. Phillips will step down effective November 10, 2017, and will provide financial, accounting and transition services as a consultant to Novavax until December 31, 2017. Mr. Erck will act as the interim CFO pending completion of a search for a new Chief Financial Officer.
“Buck has been instrumental in a number of significant Novavax accomplishments, and we thank him for all his contributions over the last four years. We wish him all the best in his new endeavors,” said Stanley C. Erck, President and CEO of Novavax.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
[email protected]
240-268-2000
